Get the app
NSEHealthcare

Aarti Drugs Limited (AARTIDRUGS)

NSE · Healthcare · Drug Manufacturers - Specialty & Generic

₹428.35+0.95%
Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue
₹703 cr
Revenue YoY
+19.0%
Net profit
₹50 cr
Profit YoY
-6.9%
EPS
₹5.66
EPS estimate
₹5.40
Net margin
7.1%

EPS came in at 5.66 against a street estimate of 5.40 — a beat of 4.8%.

Key statistics

Market cap
₹3,911 cr
P/E
20.5
Forward P/E
0.0
P/B
2.52
Book value
₹169.79
EPS (TTM)
₹20.95
52-week high
₹531.70
52-week low
₹318.95
50-day MA
₹415.16
200-day MA
₹384.81
Beta
0.31

Analyst view

with an average price target of ₹474.00.

Shareholding

Promoters
59.56%
Institutions
11.10%

Recent filings & reports

DocumentDate
Annual report FY2026
AARTI DRUGS LIMITED - ANNUAL REPORT FY 2025-26 SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Total Revenue: ₹2,568 crores (consolidated basis) • E
2026-09-02
Q1 FY27 earnings call
AARTI DRUGS LIMITED – Q1 FY27 EARNINGS SUMMARY HEADLINE NUMBERS • Revenue (Consolidated): INR 703.6 crores (Q1 FY27) vs INR 590.8 crores (Q1 FY26) –
2026-08-07
Investor presentation
AARTI DRUGS LIMITED – Q1 FY27 INVESTOR SUMMARY HEADLINE NUMBERS • Total Revenue: ₹704 crores in Q1 FY27, up 19% YoY from ₹591 crores in Q1 FY26 • EB
2026-08-01
Q4 FY26 earnings call
AARTI DRUGS LIMITED – Q4 & FY26 EARNINGS SUMMARY HEADLINE NUMBERS • Q4 FY26 consolidated revenue: INR 721.1 crores (vs INR 678.6 crores in Q4 FY25;
2026-05-23
Investor presentation · Q4 FY26
AARTI DRUGS LIMITED – Q4 & FY26 INVESTOR PRESENTATION SUMMARY HEADLINE NUMBERS • FY26 Total Revenue: Rs 2,567.7 crore (+7% YoY vs Rs 2,403.4 crore i
2026-05-16
Quarterly results · Q4 FY26
AARTI DRUGS LIMITED – FINANCIAL SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS STANDALONE (Year ended March 31, 2026) • Total Income: ₹2,40,339 lakhs
2026-05-15
Q3 FY26 earnings call
AARTI DRUGS LIMITED – Q3 FY26 EARNINGS SUMMARY HEADLINE NUMBERS • Q3 FY26 Revenue (Consolidated): INR 602.9 crores vs. INR 557.1 crores in Q3 FY25 (
2026-02-10
Quarterly results · Q3 FY26
AARTI DRUGS LIMITED – FINANCIAL RESULTS SUMMARY Quarter & Nine Months Ended December 31, 2025 --- HEADLINE NUMBERS • Q3 FY2025-26 Revenue from Oper
2026-02-03

Readable in the app.

Corporate actions

ActionDetailDate
Dividend₹2 / share
ex-date Feb 9, 2026
2026-02-09

Deals & corporate news

AnnouncementDate
Interim dividend of Rs. 2 per equity share declared
Aarti Drugs Limited's Board of Directors declared an interim dividend of Rs. 2 per equity share on February 03, 2026. An interim dividend is a cash payment distributed to shareholders before
2026-02-03

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Aarti Drugs Limited — free to start.

Google PlayApp Store

Other Healthcare companies

Data updated 2026-09-18.